Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection

JCI Insight. 2023 Oct 9;8(19):e167215. doi: 10.1172/jci.insight.167215.

Abstract

Tregs expressing chimeric antigen receptors (CAR-Tregs) are a promising tool to promote transplant tolerance. The relationship between CAR structure and Treg function was studied in xenogeneic, immunodeficient mice, revealing advantages of CD28-encoding CARs. However, these models could underrepresent interactions between CAR-Tregs, antigen-presenting cells (APCs), and donor-specific Abs. We generated Tregs expressing HLA-A2-specific CARs with different costimulatory domains and compared their function in vitro and in vivo using an immunocompetent model of transplantation. In vitro, the CD28-encoding CAR had superior antigen-specific suppression, proliferation, and cytokine production. In contrast, in vivo, Tregs expressing CARs encoding CD28, ICOS, programmed cell death 1, and GITR, but not 4-1BB or OX40, all extended skin allograft survival. To reconcile in vitro and in vivo data, we analyzed effects of a CAR encoding CD3ζ but no costimulatory domain. These data revealed that exogenous costimulation from APCs can compensate for the lack of a CAR-encoded CD28 domain. Thus, Tregs expressing a CAR with or without CD28 are functionally equivalent in vivo, mediating similar extension of skin allograft survival and controlling the generation of anti-HLA-A2 alloantibodies. This study reveals a dimension of CAR-Treg biology and has important implications for the design of CARs for clinical use in Tregs.

Keywords: Costimulation; Immunology; Immunotherapy; Tolerance; Transplantation.

MeSH terms

  • Allografts / metabolism
  • Animals
  • CD28 Antigens
  • Mice
  • Receptors, Chimeric Antigen*
  • T-Lymphocytes, Regulatory
  • Transplantation, Homologous

Substances

  • Receptors, Chimeric Antigen
  • CD28 Antigens